CoChat

Synergistic co‐targeting of prostate‐specific membrane antigen and androgen receptor in prostate cancer

Murga, Jose D., Moorji, Sameer M., Han, Amy Q., Magargal, Wells W., DiPippo, Vincent A., Olson, William C. · 2015 · The Prostate
Cited by 102

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Antibody–drug conjugates (ADCs) are an emerging class of cancer therapies that have demonstrated favorable activity both as single agents and as components of combination regimens. Phase 2 testing of an ADC targeting prostate‐specific membrane antigen (PSMA) in advanced prostate cancer has shown antitumor activity. The present study examined PSMA ADC used in combination with potent antiandrogens (enzalutamide and abiraterone) and other compounds. METHODS: Antiproliferative activity and expression of PSMA, prostate‐specific antigen and androgen receptor were evaluated in the prostate cancer cell lines LNCaP and C4‐2. Cells were tested for susceptibility to antiandrogens or other inhibitors, used alone and in combination with PSMA ADC. Potential drug synergy or antagonism was evaluated using the Bliss independence method. RESULTS: Enzalutamide and abiraterone demonstrated robust, statistically significant synergy when combined with PSMA ADC. Largely additive activity was observed between the antiandrogens and the individual components of the ADC (free drug and unmodified antibody). Rapamycin also synergized with PSMA ADC in certain settings. Synergy was linked in part to upregulation of PSMA expression. In androgen‐dependent LNCaP cells, enzalutamide and abiraterone each inhibited proliferation, upregulated PSMA expression, and synergized with PSMA ADC. In androgen‐independent C4‐2 cells, enzalutamide and abiraterone showed no measurable antiproliferative activity on their own but increased PSMA expression and synergized with PSMA ADC nonetheless. PSMA expression increased progressively over 3 weeks with enzalutamide and returned to baseline levels 1 week after enzalutamide removal. CONCLUSIONS: The findings support exploration of clinical treatment regimens that combine potent antiandrogens and PSMA‐targeted therapies for prostate cancer. Prostate 75:242–254, 2015. © 2014 Wiley Periodicals, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pros.22910

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 102

Metadata

Authors
Murga, J. D., Moorji, S. M., Han, A. Q., Magargal, W. W., DiPippo, V. A., & Olson, W. C.
Venue
The Prostate
Publisher
Wiley
Published
2014-10-18
Volume
75
Issue
3
Pages
242-254
ISSN
  • 0270-4137 (ISSN-L)
  • 1097-0045
OpenAlex
W1924415983
Cited by
102
References
10
FWCI
3.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synergistic co‐targeting of prostate‐specific membrane antigen and androgen receptor in prostate cancer. https://app.cochat.ai/papers/10.1002/pros.22910
The paper
Murga, J. D., Moorji, S. M., Han, A. Q., Magargal, W. W., DiPippo, V. A., & Olson, W. C. (2015). Synergistic co‐targeting of prostate‐specific membrane antigen and androgen receptor in prostate cancer. The Prostate. https://doi.org/10.1002/pros.22910

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.